Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-β axis.
Ma X, Wang Q, Sun C, Agarwal I, Wu H, Chen J, Zhao C, Qi G, Teng Q, Yuan C, Yan S, Peng J, Li R, Song K, Zhang Q, Kong B.
Ma X, et al. Among authors: kong b.
Cell Rep. 2023 Aug 29;42(8):112944. doi: 10.1016/j.celrep.2023.112944. Epub 2023 Aug 10.
Cell Rep. 2023.
PMID: 37566545
Free article.